​

Edwards Lifesciences (EW) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

EW Stock Forecast

Edwards Lifesciences (EW) stock forecast, based on 48 Wall Street analysts, predicts a 12-month average price target of $97.25, with a high of $110.00 and a low of $87.00. This represents a 23.55% increase from the last price of $78.71.

$60 $70 $80 $90 $100 $110 High: $110 Avg: $97.25 Low: $87 Last Closed Price: $78.71

EW Stock Rating

Edwards Lifesciences stock's rating consensus is Buy, based on 48 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 32 Buy (66.67%), 16 Hold (33.33%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 48 16 32 0 Strong Sell Sell Hold Buy Strong Buy

EW Price Target Upside V Benchmarks

TypeNameUpside
StockEdwards Lifesciences23.55%
SectorHealthcare Stocks 15.45%
IndustryMedical Device Stocks22.47%

Price Target Trends

1M3M12M
# Anlaysts62136
Avg Price Target$98.50$96.90$93.97
Last Closing Price$78.71$78.71$78.71
Upside/Downside25.14%23.11%19.39%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Feb, 2651612--33
Jan, 2651513--33
Dec, 2541514--33
Nov, 2541415--33
Oct, 25413151-33
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 04, 2026Danielle AntalffyUBS$94.00$81.6315.15%19.43%
Jan 20, 2026Stifel Nicolaus$110.00$84.3530.41%39.75%
Jan 20, 2026Piper Sandler$98.00$84.3516.18%24.51%
Jan 12, 2026Danielle AntalffyUBS$95.00$83.5813.66%20.70%
Jan 12, 2026Robert W. Baird$90.00$83.697.54%14.34%
Jan 12, 2026Barclays$104.00$85.1322.17%32.13%
Jan 09, 2026David RomanGoldman Sachs$108.00$84.5827.69%37.21%
Jan 07, 2026Rick WiseStifel Nicolaus$105.00$85.8522.31%33.40%
Jan 05, 2026Evercore ISI$94.00$84.3511.44%19.43%
Dec 18, 2025Wells Fargo$100.00$84.8417.87%27.05%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 04, 2026UBSNeutralNeutralhold
Jan 20, 2026Piper SandlerOverweightOverweighthold
Jan 12, 2026UBSNeutralNeutralhold
Jan 12, 2026BarclaysOverweightOverweighthold
Jan 09, 2026Cowen & Co.HoldBuyupgrade
Jan 09, 2026Goldman SachsBuyBuyhold
Jan 05, 2026Evercore ISIOutperformOutperformhold
Dec 11, 2025CitigroupBuyBuyhold
Dec 08, 2025BarclaysOverweightOverweighthold
Dec 05, 2025RBC CapitalOutperformOutperformhold

Financial Forecast

EPS Forecast

$2 $3 $4 $5 $6 $7 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.41$2.46$2.31$6.98----
Avg Forecast$2.26$2.46$2.51$2.57$2.44$2.74$3.11$3.49
High Forecast$2.43$2.55$2.52$2.60$2.53$2.96$3.40$3.66
Low Forecast$2.14$2.40$2.48$2.42$2.42$2.41$2.82$3.44
Surprise %6.64%--7.97%171.60%----

Revenue Forecast

$5B $6B $6B $7B $8B $9B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$5.23B$5.38B$6.00B$5.44B----
Avg Forecast$5.26B$5.37B$5.97B$5.80B$5.82B$6.40B$7.09B$7.77B
High Forecast$5.55B$5.52B$6.00B$5.86B$5.86B$6.43B$7.16B$8.07B
Low Forecast$5.03B$5.26B$5.94B$5.33B$5.79B$6.37B$7.02B$7.69B
Surprise %-0.51%0.25%0.59%-6.14%----

Net Income Forecast

$1B $2B $2B $3B $4B $5B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.50B$1.52B$1.40B$4.17B----
Avg Forecast$1.39B$1.53B$1.40B$1.57B$1.51B$1.59B$1.89B$2.12B
High Forecast$1.67B$1.84B$1.68B$1.58B$1.54B$1.81B$2.07B$2.23B
Low Forecast$1.11B$1.22B$1.12B$1.47B$1.48B$1.47B$1.72B$2.09B
Surprise %8.09%-0.49%-166.36%----

EW Forecast FAQ

Is Edwards Lifesciences stock a buy?

Edwards Lifesciences stock has a consensus rating of Buy, based on 48 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 32 Buy, 16 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Edwards Lifesciences is a favorable investment for most analysts.

What is Edwards Lifesciences's price target?

Edwards Lifesciences's price target, set by 48 Wall Street analysts, averages $97.25 over the next 12 months. The price target range spans from $87 at the low end to $110 at the high end, suggesting a potential 23.55% change from the previous closing price of $78.71.

How does Edwards Lifesciences stock forecast compare to its benchmarks?

Edwards Lifesciences's stock forecast shows a 23.55% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the medical device stocks industry (22.47%).

What is the breakdown of analyst ratings for Edwards Lifesciences over the past three months?

  • February 2026: 15.15% Strong Buy, 48.48% Buy, 36.36% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 15.15% Strong Buy, 45.45% Buy, 39.39% Hold, 0% Sell, 0% Strong Sell.
  • December 2025: 12.12% Strong Buy, 45.45% Buy, 42.42% Hold, 0% Sell, 0% Strong Sell.

What is Edwards Lifesciences’s EPS forecast?

Edwards Lifesciences's average annual EPS forecast for its fiscal year ending in December 2025 is $2.44, marking a -65.04% decrease from the reported $6.98 in 2024. Estimates for the following years are $2.74 in 2026, $3.11 in 2027, and $3.49 in 2028.

What is Edwards Lifesciences’s revenue forecast?

Edwards Lifesciences's average annual revenue forecast for its fiscal year ending in December 2025 is $5.82B, reflecting a 7.08% increase from the reported $5.44B in 2024. The forecast for 2026 is $6.4B, followed by $7.09B for 2027, and $7.77B for 2028.

What is Edwards Lifesciences’s net income forecast?

Edwards Lifesciences's net income forecast for the fiscal year ending in December 2025 stands at $1.51B, representing a -63.82% decrease from the reported $4.17B in 2024. Projections indicate $1.59B in 2026, $1.89B in 2027, and $2.12B in 2028.